Issues related to drug pricing; pharmaceutical supply chain; modernization of prescribing information for physicians and pharmacists; Increasing Transparency in Generic Drug Applications, S.1302 and H.R. 1843; Part D Formulary Design and Generic Drug Testing
Source-reported fields
Filing overview
- Type
- 1st Quarter - Amendment
- Posted
- Apr 21, 2025
- Income
- $60,000.00
- Expenses
- Not reported
- Registrant
- S-3 GROUP
- Client
- VIATRIS (MYLAN, INC)
- Filing UUID
- fa5ac834-f8d8-4d0a-9b56-37124f204b8d
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.